XTX Topco Ltd Makes New $389,000 Investment in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

XTX Topco Ltd bought a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,827 shares of the company's stock, valued at approximately $389,000.

A number of other hedge funds have also modified their holdings of the business. HighTower Advisors LLC acquired a new stake in shares of PROCEPT BioRobotics during the third quarter worth $279,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of PROCEPT BioRobotics during the third quarter worth $64,000. Franklin Resources Inc. lifted its holdings in shares of PROCEPT BioRobotics by 64.5% during the third quarter. Franklin Resources Inc. now owns 885,992 shares of the company's stock worth $64,669,000 after purchasing an additional 347,330 shares during the period. Lord Abbett & CO. LLC lifted its holdings in shares of PROCEPT BioRobotics by 45.3% during the third quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company's stock worth $59,974,000 after purchasing an additional 233,430 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of PROCEPT BioRobotics by 290.2% during the third quarter. Principal Financial Group Inc. now owns 68,617 shares of the company's stock worth $5,498,000 after purchasing an additional 51,030 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Price Performance

PRCT traded up $1.67 on Monday, hitting $54.16. 998,224 shares of the company were exchanged, compared to its average volume of 810,718. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The business's fifty day moving average is $57.48 and its 200 day moving average is $73.87. PROCEPT BioRobotics Co. has a fifty-two week low of $47.04 and a fifty-two week high of $103.81. The firm has a market capitalization of $2.97 billion, a P/E ratio of -27.77 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.04. The business had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company's quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.51) earnings per share. As a group, sell-side analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Morgan Stanley decreased their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Bank of America reduced their target price on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Friday. Finally, Truist Financial cut their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $90.00.

Insider Activity

In related news, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Kevin Waters sold 733 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock worth $368,322 over the last ninety days. 17.40% of the stock is currently owned by insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).